Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Alzheimer Disease
and you are
The phase for this study is not defined.
Show me locations

The purpose

The combined measurement of Ab42 and tau protein (total and phosphorylated) in the spinal fluid has been shown to be promising in the diagnosis of Alzheimer's disease (AD), and has justified its inclusion new diagnostic criteria. However, it can sometimes yield discordant results that are not discriminant (isolated variation in Ab42 or P-181 Tau). To answer this challenge, a new marker has been developed in recent years, namely amyloid beta-peptide 1-40 (Aβ40). This marker reflects the patient's total amyloid deposits and is used to calculate the Aβ42/Aβ40 ratio. This ratio measures the relative variation of Aβ42 as compared to the total amyloid burden. Literature data on this topic are sparse and to date, no report has been published evaluating the utility of this marker in the diagnostic strategy for AD.

Provided treatments

  • Biological: spinal fluid collection
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02770482. The sponsor of the trial is CHU de Reims and it is looking for 200 volunteers for the current phase.
Official trial title:
Utility of Amyloid Beta-peptide 1-40 Measurement in the Diagnosis of Alzheimer's Disease